[{"data":1,"prerenderedAt":162},["ShallowReactive",2],{"drug-selegiline":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":22,"regimens":37,"contraindications":68,"warnings":78,"renal":85,"monitoring":86,"interactions":87,"review":88,"examples":91,"atc":97,"iran":99,"usApproval":111,"links":117,"populations":136},"selegiline",1,{"fa":7,"en":8},"سلژیلین","Selegiline","nervous-system",{"fa":11,"en":12},"مهارکننده MAO-B","MAO-B inhibitor",[14],{"name":15,"market":16},"Eldepryl","US",[18,19,20,7,21],"eldepryl","jumex","جومکس","سلگیلین",[23],{"id":24,"form":25,"route":26,"label":27,"concentration":28,"markets":32,"refs":33},"cap-5","capsule","oral","5 mg capsule",{"amount":29,"unit":30,"perUnit":25,"scored":31},5,"mg",false,[16],[34],{"source":35,"section":36},"fda-selegiline","How Supplied",[38],{"id":39,"disease":40,"label":41,"population":44,"type":48,"unit":30,"dose":49,"refs":51,"limits":54,"notes":60},"pd","parkinsons",{"fa":42,"en":43},"پارکینسون با پاسخ رو به کاهش به لوودوپا — ۵ mg هنگام صبحانه و ۵ mg هنگام ناهار","Parkinson disease with waning levodopa response — 5 mg at breakfast and 5 mg at lunch",{"minAge":45},{"value":46,"unit":47},18,"year","fixed",{"perDose":29,"dosesPerDay":50},2,[52],{"source":35,"section":53},"Dosage and Administration",{"maxPerDay":55,"refs":56},10,[57,58],{"source":35,"section":53},{"source":35,"section":59},"Warnings",[61],{"text":62,"refs":65},{"fa":63,"en":64},"همراه لوودوپا\u002Fکاربیدوپا؛ پس از ۲ تا ۳ روز می‌توان لوودوپا را ۱۰ تا ۳۰٪ کم کرد. بیش از ۱۰ mg\u002Fروز انتخابی بودن MAO-B از بین می‌رود.","With levodopa\u002Fcarbidopa; after 2–3 days levodopa may be cut by 10–30%. Above 10 mg\u002Fday MAO-B selectivity is lost.",[66,67],{"source":35,"section":53},{"source":35,"section":59},[69],{"id":70,"severity":71,"text":72,"refs":75},"ci","block",{"fa":73,"en":74},"حساسیت به سلژیلین؛ مپریدین (و معمولاً سایر اپیوئیدها).","Hypersensitivity to selegiline; meperidine (often extended to other opioids).",[76],{"source":35,"section":77},"Contraindications",[79],{"text":80,"refs":83},{"fa":81,"en":82},"بیش از ۱۰ mg\u002Fروز نه (مهار غیرانتخابی MAO)؛ واکنش فشار خون با غذای تیرامین‌دار نادر است.","Not above 10 mg\u002Fday (non-selective MAO inhibition); rare hypertensive reactions with tyramine-rich foods.",[84],{"source":35,"section":59},[],[],[],{"status":89,"reviewer":90,"date":90},"unverified",null,[92],{"regimen":39,"formulation":24,"input":93,"expect":96},{"ageYears":94,"weightKg":95},65,70,{"perDose":29,"tabletsPerDoseRounded":5,"perDay":55},[98],"N04BD01",{"status":100,"forms":101,"refs":106},"registered",[102],{"code":103,"en":104,"fa":105},"01121","SELEGILINE HCL 5MG TAB","قرص سلجیلین هیدروکلراید ۵ میلی‌گرم",[107],{"source":108,"section":109,"url":110},"darooyab-generic","G-2499\u002FSelegiline","https:\u002F\u002Fwww.darooyab.ir\u002FG-2499\u002FSelegiline",{"kind":112,"refs":113,"id":116},"ANDA",[114],{"source":35,"section":115},"SPL approval \u002F marketing category","ANDA075321",[118,121,125,128,131,134],{"kind":119,"url":120,"label":116},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=075321",{"kind":122,"url":123,"label":124},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=1924db3d-6a16-4496-cfd0-6903be146925","FDA Selegiline caps",{"kind":126,"url":127,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa697046.html",{"kind":126,"url":129,"label":130},"https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa607003.html","Selegiline Transdermal Patch",{"kind":132,"url":133,"label":98},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=N04BD01",{"kind":135,"url":110,"label":8},"darooyab",{"pregnancy":137,"lactation":146,"pediatric":154},{"level":138,"text":139,"quote":142,"refs":143},"caution",{"fa":140,"en":141},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Pregnancy Category C No teratogenic effects were observed in a study of embryo-fetal development in Sprague-Dawley rats at oral doses of 4, 12, and 36 mg\u002Fkg or 4, 12 and 35 times the human therapeutic dose on a mg\u002Fm 2 basis.",[144],{"source":35,"section":145},"Pregnancy",{"level":138,"text":147,"quote":150,"refs":151},{"fa":148,"en":149},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Because many drugs are excreted in human milk, consideration should be given to discontinuing the use of all but absolutely essential drug treatments in nursing women.",[152],{"source":35,"section":153},"Nursing Mothers",{"level":138,"text":155,"quote":158,"refs":159},{"fa":156,"en":157},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The effects of selegiline hydrochloride in children have not been evaluated.",[160],{"source":35,"section":161},"Pediatric Use",1792191566007]